Regeneron Reports Strong Q1 Results, Authorizes New $3.0 Billion Share Repurchase, and Secures Strategic Government Pricing Agreement
REGN sits 54% above its 52-week low of $476.487.
Summary
Regeneron announced strong Q1 2026 financial results, a new $3.0 billion share repurchase program, a strategic drug pricing agreement with the U.S. government, and key regulatory approvals.
Key Events · Earnings and Guidance · REGN
-
Strong First Quarter Financial Performance
Total revenues increased 19% to $3.6 billion, and non-GAAP diluted EPS rose 15% to $9.47, driven by strong Dupixent and EYLEA HD sales. GAAP net income and EPS saw a slight decrease.
-
New $3.0 Billion Share Repurchase Program Authorized
The board of directors authorized a new program to repurchase up to an additional $3.0 billion of common stock, following $803 million in repurchases during Q1 2026.
-
Strategic U.S. Government Pricing Agreement
Regeneron entered into agreements with the U.S. government for Most-Favored-Nation Pricing on certain products, in exchange for not being subject to future government pricing mandates and receiving tariff relief for three years.
-
Key Regulatory Approvals and Pipeline Progress
The FDA approved EYLEA HD for extended dosing intervals up to 5 months, Dupixent for CSU in young children and AFRS, and Otarmeni (gene therapy) for genetic hearing loss. An NDA for cemdisiran was submitted, and a BLA for garetosmab received priority review.
Analysis · REGN · Life Sciences
Regeneron Pharmaceuticals reported robust first-quarter 2026 financial results, with total revenues increasing 19% and non-GAAP diluted EPS rising 15%. The company also announced a significant new $3.0 billion share repurchase program, signaling strong confidence in its financial position and commitment to returning capital to shareholders. A strategic agreement with the U.S. government on drug pricing, including Most-Favored-Nation pricing for certain products, provides clarity and avoids future pricing mandates, while extending EYLEA's market exclusivity through a biosimilar settlement further strengthens its commercial outlook. These positive developments, alongside key regulatory approvals for EYLEA HD and the gene therapy Otarmeni, outweigh the temporary manufacturing interruption and mixed GAAP earnings.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $732.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.4B. The 52-week trading range was $476.49 to $821.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.